Admetsys

Info

Contact Glenn Robertelli
Title COO
Email glenn.robertelli@admetsys.com
Phone 800-755-8895

Description

Diabetes is the fastest-growing cause of inpatient and surgical care costs in the world. Worldwide spending on diabetic care already exceeds $400 billion annually, with 43% of these costs coming from hospital care in Europe and the United States.
Over 40% of patients admitted to hospital are now at diabetic risk. Despite this, techniques for controlling glucose levels in hospitalized patients have remained unchanged for nearly three decades, and are too imprecise, labor-intensive, and coarsely implemented to address the growing need.
Admetsys has developed the first fully-automated glucose control system specifically for the needs of hospital and surgical care. The system attaches to a patient’s intravenous line, and automatically measures blood glucose concentration in real time with no blood loss. From this, it creates an adaptive, computational model of each patient’s metabolism, and infuses precisely-optimized, counterbalancing treatment—insulin to reduce high glycemic levels and glucose to raise and support falling levels.
Proper control of blood glucose levels and avoidance of harmful low levels saves lives (34% mortality reduction), decreases complications (by 40–50% over numerous co-morbidities), and speeds recovery (by 1.8 days in critical care patients). Foremost, this is a fundamental standard of care issue, increasingly cited by regulatory and standards bodies. Understanding of this need is becoming a key financial driver for hospitals as well, with impact both on revenue (from outcome-based reimbursement) and cost savings (independently shown to be $7,500+ per patient).

Company News

Admetsys is accepted into the Second TiE ScaleUp Cohort

/
DateJun 28, 2016
This year’s TiE ScaleUp Cohort includes the following companies, several of them being alums of MassChallenge, TechStars, Harvard i-Lab and Learn Launch: Admetsys, Advanced Continuing Education Association, Avrio, Blackburn Energy, Cintell, Entromy, HelloToken, KnipBio, Nested Bean, Neumitra, Renew Energy Partners, Rifiniti, Shearwater and Wizdy.

Admetsys is accepted into the Dreamit Health 2016 accelerator class

/
DateMar 24, 2016
Admetsys has developed an artificial pancreas device that measures, models, and treats patients at diabetic risk. Admetsys is one of the 15 health startups that will join the next Dreamit Health accelerator class.

Admetsys Awarded Top Company at the 2015 Digital European Venture Summit

/
DateJun 2, 2015
Admetsys has been awarded Top Company by Tech Tour and the European Venture Contest at the 2015 Digital Health Venture Forum and has been nominated to present its Smart Pancreas™ technology for hospitalized diabetics at the 2015 European Venture Summit in Düsseldorf, Germany.

Admetsys wins Worcester's Five Minute Pitch Contest

/
DateApr 15, 2015
Boston-based Admetsys was the winner of The Venture Forum's ninth annual Five-Minute-Pitch contest, held in Worcester Tuesday. Admetsys CEO Jeff Valk gave the winning presentation, earning the $2,500 first prize and the $1,000 audience choice award.

Admetsys Wins Top Prize at SXSW Hatch Pitch competition

/
DateMar 16, 2015
At the Hatch pitch competition five companies came away victorious including Admetsys. The winners received first round interview at Entrepreneurs Roundtable Accelerator; slots in two other accelerators; credits for services from Microsoft and Amazon; entrepreneur office hours.